CorestemChemon (ChemOn)
South Korea's first private non-clinical CRO, providing GLP toxicity, safety pharmacology, pharmacokinetic and efficacy studies for drugs, chemicals and biologics.
9 contract research organizations in our directory list both Repeat-Dose Toxicity and Mouse among their capabilities, across 5 countries. 9 report GLP capability and 3 report AAALAC accreditation. Confirm species-specific experience with each lab when you get in touch.
Showing 9 CROs. Order rotates daily so no lab is permanently listed first.
South Korea's first private non-clinical CRO, providing GLP toxicity, safety pharmacology, pharmacokinetic and efficacy studies for drugs, chemicals and biologics.
Government-funded Korean research institute providing GLP nonclinical safety studies, including inhalation toxicology, safety pharmacology and reproductive toxicity.
GLP-accredited preclinical CRO headquartered in Denmark with sites in Sweden, Austria and the UK. Known for Gottingen minipig work and regulatory toxicology, with discovery pharmacology including CNS and…
Bengaluru-based preclinical CRO, part of Eurofins, offering GLP safety assessment, DMPK and discovery services for pharmaceutical and agrochemical sponsors.
Indian GLP CRO providing regulatory toxicology and safety studies for pharmaceuticals, agrochemicals, chemicals and biologics.
Independent German preclinical CRO conducting GLP toxicology, reproductive toxicology, carcinogenicity and safety pharmacology studies across rodent and non-rodent species.
Korean non-clinical CRO offering IND and NDA-enabling GLP toxicology, including general, reproductive and genetic toxicity, carcinogenicity and safety pharmacology, with NHP capacity through its group companies.
Italian GLP CRO near Rome providing regulatory toxicology and safety studies for pharmaceuticals, chemicals and agrochemicals.
Non-clinical CRO near Milan and part of the NMS Group, offering GLP safety assessment and toxicology, safety pharmacology and preclinical regulatory consulting to move candidates toward IND/CTA.